Trials / Conditions / Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

20 registered clinical trials studyying Recurrent Glioblastoma Multiforme — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) NCT04915404	WPD Pharmaceuticals Sp. z o.o.	Phase 1 / Phase 2
Unknown	The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma NCT05868083	Shanghai Simnova Biotechnology Co.,Ltd.	Phase 1
Unknown	A Prospective, Open-label, Single-arm Clinical Study NCT04689087	Sun Yat-sen University	N/A
Recruiting	A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain C NCT03423628	AstraZeneca	Phase 1
Completed	Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multifor NCT01934361	Novartis Pharmaceuticals	Phase 1
Active Not Recruiting	Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma NCT02062827	University of Alabama at Birmingham	Phase 1
Completed	Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients NCT01738646	Duke University	Phase 2
Terminated	Post-approval Study of NovoTTF-100A in Recurrent GBM Patients NCT01756729	NovoCure Ltd.	Phase 4
Unknown	Procarbazine and Lomustine in Recurrent Glioblastoma NCT01737346	Incheon St.Mary's Hospital	Phase 2
Completed	Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumo NCT01576666	Novartis Pharmaceuticals	Phase 1
Completed	Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme NCT01464177	Andre Tsin Chih Chen	Phase 2
Completed	Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme NCT00883298	Center for Neurosciences, Tucson	Phase 2
Completed	Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors NCT00747253	Monteris Medical	Phase 1
Unknown	CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan NCT00562419	Adnexus, A Bristol-Myers Squibb R&D Company	Phase 2
Completed	Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM NCT00597493	Duke University	Phase 2
Completed	Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to NCT00481455	CASI Pharmaceuticals, Inc.	Phase 2
Completed	Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme NCT00509301	Peregrine Pharmaceuticals	Phase 1
Completed	Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) NCT00379470	NovoCure Ltd.	Phase 3
Completed	Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma NCT00306618	CASI Pharmaceuticals, Inc.	Phase 2
Completed	Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors NCT00071539	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2